Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on February 7, 2002

Arteriosclerosis, Thrombosis, and Vascular Biology. 2002
Published online before print February 7, 2002, doi: 10.1161/01.ATV.0000012665.51263.B7
A more recent version of this article appeared on April 1, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/4/530    most recent
01.ATV.0000012665.51263.B7v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicolaes, G. A.F.
Right arrow Articles by Dahlbäck, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Nicolaes, G. A.F.
Right arrow Articles by Dahlbäck, B.
Related Collections
Right arrow Anticoagulant mechanisms
Right arrow Deep vein thrombosis
Right arrow Coagulation
Right arrow Thrombophilia
Right arrow Thrombosis risk factors

Submitted on October 2, 2001
Accepted on January 28, 2002

Factor V and Thrombotic Disease. Description of a Janus-Faced Protein

Gerry A.F. Nicolaes and Björn Dahlbäck *

From the Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, The Wallenberg Laboratory, University Hospital Malmö, Malmö, Sweden. Dr Nicolaes is now at the Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.

* To whom correspondence should be addressed. E-mail: bjorn.dahlback{at}klkemi.mas.lu.se.

Abstract—The generation of thrombin by the prothrombinase complex constitutes an essential step in hemostasis, with thrombin being crucial for the amplification of blood coagulation, fibrin formation, and platelet activation. In the prothrombinase complex, the activated form of coagulation factor V (FVa) is an essential cofactor to the enzyme-activated factor X, with enzyme-activated factor X being virtually ineffective in the absence of its cofactor. Besides its procoagulant potential, intact factor V (FV) has an anticoagulant cofactor capacity functioning in synergy with protein S and activated protein C (APC) in APC-catalyzed inactivation of the activated form of factor VIII. The expression of anticoagulant cofactor function of FV is dependent on APC-mediated proteolysis of intact FV. Thus, FV has the potential to function in procoagulant and anticoagulant pathways, with its functional properties being modulated by proteolysis exerted by procoagulant and anticoagulant enzymes. The procoagulant enzymes factor Xa and thrombin are both able to activate circulating FV to FVa. The activity of FVa is, in turn, regulated by APC together with its cofactor protein S. In fact, the regulation of thrombin formation proceeds primarily through the upregulation and downregulation of FVa cofactor activity, and failure to control FVa activity may result in either bleeding or thrombotic complications. A prime example is APC resistance, which is the most common genetic risk factor for thrombosis. It is caused by a single point mutation in the FV gene (factor VLeiden) that not only renders FVa less susceptible to the proteolytic inactivation by APC but also impairs the anticoagulant properties of FV. This review gives a description of the dualistic character of FV and describes the gene-gene and gene-environment interactions that are important for the involvement of FV in the etiology of venous thromboembolism.


Key words: factor V • activated protein C resistance • factor VLeiden • thrombosis • protein C